Astellas Stays Competitive in Hot Gut Cancer Target, Paying $130M to License Evopoint Drug
Astellas Pharma already has the first FDA approval for a therapy that goes after Claudin 18.2, a protein whose overexpression ...
Astellas Pharma already has the first FDA approval for a therapy that goes after Claudin 18.2, a protein whose overexpression ...
In a year marked by European Parliament elections and setting of the European Union’s priorities for the next five years, ...
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.